Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is set to release its first quarter 2023 financial results after market close on May 4, 2023. The announcement includes a live conference call and webcast scheduled for 4:30 p.m. ET, with dial-in numbers provided for U.S. and international participants.
The company focuses on developing specialty pharmaceuticals aimed at serious medical conditions. Collegium's commitment to improving patient lives underlines its strategic positioning within the pharmaceutical sector. The earnings call will offer insights into Collegium's financial performance and future outlook, attracting attention from investors keen on the company's financial metrics.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in a fireside chat during the 22nd Annual Needham Healthcare Conference, scheduled for April 18, 2023, at 2:15 p.m. ET. The event will be held virtually from April 17-20, 2023. Investors can access the live webcast through the Investors section on Collegium's website. A replay will be available for 90 days post-event. Collegium is known for its commitment to enhancing the lives of those affected by serious medical conditions, with its headquarters based in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) reported record net revenue of $129.6 million for Q4 2022 and $463.9 million for FY 2022, compared to $27.4 million and $276.9 million respectively in the previous year. The company exited 2022 with a cash balance of $173.7 million and reaffirmed its 2023 guidance, projecting product revenues between $565 million and $580 million. Collegium implemented strategic initiatives, including acquiring BDSI, achieving $85 million in annual synergies, and resolving all 27 opioid-related lawsuits. The company also initiated a $100 million share repurchase program.
Collegium Pharmaceutical (Nasdaq: COLL) has released its inaugural Environmental, Social and Governance (ESG) report, showcasing its commitment to ethical business practices. Highlights from 2022 include initiatives in corporate governance, Diversity, Equity and Inclusion (DEI), and corporate social responsibility, with over $350,000 donated to STEM initiatives. Collegium aims to reduce environmental impacts through various strategies. CEO Joe Ciaffoni emphasized the company’s dedication to ethical standards, community involvement, and shareholder value as it anticipates growth in 2023.